These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 29038020)
1. The Ca Jianfei L; Min W; Chunlai M; Bicui C; Jiming Z; Bin W Biochem Pharmacol; 2017 Dec; 146():224-232. PubMed ID: 29038020 [TBL] [Abstract][Full Text] [Related]
2. [Telbivudine-associated creatine kinase elevation in chronic hepatitis B patients]. Ren JB; Wang Y; Li HY; Sun SJ; Jia JD; Ma H Zhonghua Gan Zang Bing Za Zhi; 2012 Sep; 20(9):641-3. PubMed ID: 23207225 [TBL] [Abstract][Full Text] [Related]
3. Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Chen L; Cheng C; Chen B; Zhao Y; Zhang J; Wang B Eur J Clin Pharmacol; 2016 Feb; 72(2):235-41. PubMed ID: 26566799 [TBL] [Abstract][Full Text] [Related]
4. Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: a case report and update review. Wang YH; Wu BQ; Liu H J Dig Dis; 2015 Mar; 16(3):164-7. PubMed ID: 25043654 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652 [TBL] [Abstract][Full Text] [Related]
6. Motor development delay in offspring is associated with prenatal telbivudine exposure. Zhou C; Yu Y; Yang Q; Wang H; Hou M; Jin L; Zhang F; Sheng J; Miao M; Yang X; Huang HF Medicine (Baltimore); 2018 Mar; 97(9):e0053. PubMed ID: 29489662 [TBL] [Abstract][Full Text] [Related]
7. Effects of intermittent pressure imitating rolling manipulation on calcium ion homeostasis in human skeletal muscle cells. Zhang H; Liu H; Lin Q; Zhang G; Mason DC BMC Complement Altern Med; 2016 Aug; 16(1):314. PubMed ID: 27561948 [TBL] [Abstract][Full Text] [Related]
8. [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients]. Liu Y; Liu L; Peng D; Li W; Du Y; Jia T; Chang L; Li H Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):181-4. PubMed ID: 24824118 [TBL] [Abstract][Full Text] [Related]
9. Telbivudine for the management of chronic hepatitis B virus infection. Matthews SJ Clin Ther; 2007 Dec; 29(12):2635-53. PubMed ID: 18201580 [TBL] [Abstract][Full Text] [Related]
10. Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4. He T; Chen B; Li Y; Song Y; Wu J; Xiong B; Wang B; Long J Eur J Clin Pharmacol; 2024 Jul; 80(7):1029-1038. PubMed ID: 38502357 [TBL] [Abstract][Full Text] [Related]
11. [Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B]. Zhou Y; Zheng J; Pan H; Lu C Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):573-6. PubMed ID: 25243955 [TBL] [Abstract][Full Text] [Related]
12. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. Liu M; Cai H; Yi W J Viral Hepat; 2013 Apr; 20 Suppl 1():65-70. PubMed ID: 23458527 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523 [TBL] [Abstract][Full Text] [Related]
14. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845 [TBL] [Abstract][Full Text] [Related]
15. Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B. Ying Y; Hu YK; Jin JL; Zhang JM; Zhang WH; Huang YX BMC Gastroenterol; 2018 Apr; 18(1):45. PubMed ID: 29625557 [TBL] [Abstract][Full Text] [Related]
16. Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. Liu J; Chen T; Zhao Y J Viral Hepat; 2017 Nov; 24 Suppl 1():6-11. PubMed ID: 29082653 [TBL] [Abstract][Full Text] [Related]
17. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Kim EH; Park H; Lee KH; Ahn SH; Kim SM; Han KH Clin Mol Hepatol; 2013 Mar; 19(1):82-6. PubMed ID: 23593614 [TBL] [Abstract][Full Text] [Related]
18. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. Zou XJ; Jiang XQ; Tian DY J Viral Hepat; 2011 Dec; 18(12):892-6. PubMed ID: 22093034 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524 [TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy. Law ST; Lee MK; Lee AS; Tung Y; Li KK J Dig Dis; 2016 May; 17(5):325-33. PubMed ID: 27085094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]